Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This clinical trial is an open label Phase II study of the combination of intravenously
administered SGT-53 and gemcitabine/nab-paclitaxel in patients with metastatic pancreatic
cancer. The objective of the study is to evaluate the safety, tolerability, toxicity and
efficacy (specifically Progression Free Survival at 5.5 month (PFS5.5mos)) of this
combination therapy.